Hostname: page-component-7b7567c8c-slfcl Total loading time: 0 Render date: 2026-11-19T11:02:50.814Z Has data issue: false hasContentIssue false

Treating Depression in Dementia-patients with transcranial-pulse stimulation: an observational study

Published online by Cambridge University Press:  31 July 2026

A. R. Günes*
Affiliation:
Center of Neurostimulation
M. Rahimi
Affiliation:
Center of Neurostimulation
P. Wisniowski
Affiliation:
Center of Neurostimulation
M. Beglau
Affiliation:
Center of Neurostimulation
M. Köhne
Affiliation:
Alexius/ Josef Clinic, Neuss, Germany
C. Schmidt-Kraepelin
Affiliation:
Alexius/ Josef Clinic, Neuss, Germany
U. Sprick
Affiliation:
Center of Neurostimulation
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the 'Save PDF' action button.
Introduction

Depression plays a significant role in Alzheimer’s-type dementia(AD) and affects approximately one in five patients1 (Asmer MS et al. J Clin Psychiatry. 2018 Jul 31;79). On the other hand, depression is a risk factor for the development of dementia. Despite years of research and the discovery of numerous pathophysiological factors in their mutual influence, there is still no sufficiently reliable therapeutic approach2 (Lyketsos CG et al. Alzheimers Dement.2011;7:5). As a non-invasive brain stimulation method, transcranial pulse stimulation (TPS) is a novel procedure based on shock-waves and whose effects on cognition in AD patients show promising results in current studies3(Günes AR et al. Eur.J.N.2024;1468-1331), furthermore beneficial influence on affective symptoms were reported4 (Sprick U et al. Brain Stimul.2025;439).

Objectives

In our observational study, we investigated the effects and safetiness of TPS on depressive symptoms in 100 patients who met the criteria for AD.

Methods

Each of the 100 patients (mean age: 73,5 years; gender ratio: 5:7 (m:f)) received a total of 6 treatments within 14 days (each session with 6000 pulses, energy level 0.25 mJ/mm² and frequency 4 Hz). On the basis of individual MRI scans neuro-navigation was used to apply pulses bilaterally in the frontal (including the dorsolateral prefrontal cortex) and parietal lobe as well as the precuneus area (Image 1). Written consent and the approval of an ethics committee were obtained for all patients. Before, during and immediately after the TPS intervention, the antidepressant medication of all patients remained unchanged. To assess the intensity of depressive symptoms the Beck Depression Inventory II (BDI-II) was used before the first and after the last treatment session.

Results

36 patients had a score above 5 points in BDI-II which represents the lower threshold with an average of 18,1 points within this group, which corresponds to a mild depression. The BDI-II total score in the pre-post comparison showed a reduction in the mean value from 18,1 to 5,9 points indicating a score almost below the lower threshold (Image 2). 26 patients reported temporary mild side effects such as fatigue or a local feeling of pressure in the treated areas. There were no serious adverse effects detected in any patient.Image 1:

A two-panel medical visualization showing an axial M R I brain scan and a three-dimensional head model with a pixelated green and yellow overlay. See long description.Image 2:

A clustered bar chart comparing pre and post B D I dash I I scores for 36 individual patients. Most patients show a significant decrease in scores following treatment. See long description.

Conclusions

To our knowledge, this trial is the largest study to systematically investigate the effects of TPS on depressive symptoms in AD patients so far. The positive impact on depressive symptoms may be based in part on stimulation of the dorsolateral prefrontal cortex, which is a well established target region in the treatment of major depressive disorder using transcranial magnetic stimulation. TPS seems to be a safe approach to treat depressive symptoms in patients with AD. Further studies with a larger study population are necessary to confirm the safety and effectiveness of this novel method.

Disclosure of Interest

None Declared

Information

Type
Abstract
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2026. Published by Cambridge University Press on behalf of European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.